Andreas Neubauer

25PUBLICATIONS
105CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyImmunogenetics (incl. genetic immunology)Audiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jan 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert, Franck E Nicolini, Philipp le Coutre

|Mar 05, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.

Sebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig

|Sep 16, 2024
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Christoph Röllig, Björn Steffen, Christoph Schliemann

|Jul 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.

Fabian Acker, Jörg Chromik, Emily Tiedjen

|Jun 04, 2024
[Gastrointestinal mucosa-associated lymphoma].

Wolfgang Fischbach, Andreas Neubauer, Gabriele Reinartz

|May 08, 2024
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial.

Fabio Efficace, Michal Kicinski, Corneel Coens

Pageof 5

Frequent Collaborators

9 joint publications

Stefan W Krause

7 joint publications

Hubert Serve

6 joint publications

Elisabeth Mack

6 joint publications

Andreas Burchert